MedTrace Logo

Prospective Cohort of Kidney Transplanted Patients Receiving an Extended Releasing Tacrolimus-Everolimus Association

NCT03228576 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 16

Last updated 2019-08-28

No results posted yet for this study

Summary

The tacrolimus-Everolimus association is used as an immunospressive treatment after a kidney transplant. It combined immunosupressive properties of both products and reduce the nephrotoxicity of tacrolimus by lowering the dosage.

The commercialisation of a new extended release Tacrolimus pharmaceutical form and the lack of information justify a modality of use and tolerence evaluation of this new association, commonly used.

Conditions

  • Kidney Transplant
  • Immunosuppression

Interventions

COMBINATION_PRODUCT

Extended release Tacrolimus-Everolimus association

Envarsus® will be used as Tacrolimus Certican® will be used as Everolimus

Sponsors & Collaborators

  • Chiesi Farmaceutici S.p.A.

    collaborator INDUSTRY

  • Poitiers University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-14
Primary Completion
2018-12-18
Completion
2018-12-18

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03228576 on ClinicalTrials.gov